Abstract
MIP technology has successfully produced quantitative HER2 copy number (HER2CN) data. Studies have shown high concordance between this emerging technology and conventional methods such as fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). OncoScan, the device behind MIP technology, appraises tumor percentage in the form of percent aberrant cells (%AC). However, inability to assess tumor heterogeneity, extensive stroma within the tumor, and prominent in situ …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
